Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Standard Risk Assessment Tools Fall Short to Assess Risk in Transplant Patients

Radhika Kulkarni, Luis Fernando Gonzalez-Mosquera, Muneer H. Abidi, Josephine Emole, Edward M. Peres, Shatha Y. Farhan

Blood (2023) 142 (Supplement 1): 5063.

https://doi.org/10.1182/blood-2023-179845

Published: 2023

Journal Articles

Renal Toxicity with Carfilzomib in Multiple Myeloma: Secondary Analysis of SWOG S1304 Comparing Low-Dose Versus High-Dose Carfilzomib

Rajshekhar Chakraborty, Rachael Sexton, Suzanne Lentzsch, Muneer H. Abidi, Peter M. Voorhees, Adam D Cohen, Eric Rohren, Stephen B. Heitner, Kevin R. Kelly, Niklas J Mackler, David M. Baer, Antje Hoering, Brian G.M. Durie, Sikander Ailawadhi, Robert Z. Orlowski

Blood (2022) 140 (Supplement 1): 4349–4351.

https://doi.org/10.1182/blood-2022-166609

Published: 2022

Journal Articles

Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse

Craig H. Moskowitz, Jan Walewski, Auayporn Nademanee, Tamas Masszi, Edward Agura, Jerzy Holowiecki, Muneer H. Abidi, Andy I. Chen, Patrick Stiff, Simonetta Viviani, Veronika Bachanova, Anna Sureda, Teresa McClendon, Connie Lee, Julie Lisano, John Sweetenham

Blood (2018) 132 (25): 2639–2642.

https://doi.org/10.1182/blood-2018-07-861641

Published: 2018

Journal Articles

Longer Term Follow up of the Â Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT)

Brian GM Durie, MD, Antje Hoering, PhD, Rachael Sexton, PhD, Muneer H. Abidi, MD, Joshua Epstein, DSc, S. Vincent Rajkumar, MD, Angela Dispenzieri, MD, Stephen P. Kahanic, MD, Mohan C. Thakuri, MD, Frederic J. Reu, MD, Christopher M. Reynolds, MD, Robert Z. Orlowski, MD PhD, Bart Barlogie, MD PhD

Blood (2018) 132 (Supplement 1): 1992.

https://doi.org/10.1182/blood-2018-99-117003

Published: 2018

Journal Articles

Post-Transplant Cyclophosphamide Overcomes Graft-Versus-Host Disease Aggravation Induced By Extended Administration of Proteasome Inhibitors

A. Samer Al-Homsi, MD, Austin Goodyke, Kelli Cole, MSN, Marlee Muilenburg, BSN, Michael McLane, Sarah Abdel-Mageed, Muneer H. Abidi, MD, Stephanie F. Williams, MD

Blood (2016) 128 (22): 4543.

https://doi.org/10.1182/blood.V128.22.4543.4543

Published: 2016

Journal Articles

Bendamustine, Carfilzomib, and Melphalan (BCM) Conditioning Prior to Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: A Feasibility Study

A. Samer Al-Homsi, MD, Marlee Muilenburg, BSN, Kelli Cole, MSN, Muneer H. Abidi, MD, Stephanie F. Williams, MD

Blood (2016) 128 (22): 4635.

https://doi.org/10.1182/blood.V128.22.4635.4635

Published: 2016

Journal Articles

A Pilot Study of Peripheral Blood Hematopoietic Stem Cells Mobilization with the Combination of Bortezomib and G-CSF in Multiple Myeloma and Non-Hodgkin's Lymphoma Patients.

Divaya Bhutani, MD, Vidya sri Kondadasula, Joseph P. Uberti, MD, PhD, Voravit Ratanatharathorn, MD, Lawrence G. Lum, MD, D.Sc., Abhinav Deol, MD, Lois Ayash, MD, Muneer H. Abidi, MD

Blood (2015) 126 (23): 1902.

https://doi.org/10.1182/blood.V126.23.1902.1902

Published: 2015

Journal Articles

Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT): Results of the Randomized Phase III Trial SWOG S0777

Brian Durie, MD, Antje Hoering, PhD, S. Vincent Rajkumar, MD, Muneer H. Abidi, MD, Joshua Epstein, DSc, Stephen P. Kahanic, MD, Mohan C. Thakuri, MD, Frederic J Reu, Christopher M. Reynolds, MD, Rachael Sexton, MS, Robert Z. Orlowski, PhD, MD, Bart Barlogie, MD PhD, Angela Dispenzieri, MD

Blood (2015) 126 (23): 25.

https://doi.org/10.1182/blood.V126.23.25.25

Published: 2015

Journal Articles

Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse

John Sweetenham, Jan Walewski, MDPhDProf, Auayporn P. Nademanee, MD, Tamas Masszi, Edward Agura, Jerzy Holowiecki, Muneer H. Abidi, MD, Andy I Chen, MD PhD, Patrick Stiff, Simonetta Viviani, MD, Angelo Michele Carella, Dzhelil Osmanov, Veronika Bachanova, MD, Anna Sureda, MD PhD, Dirk Huebner, Emily K Larsen, Naomi N Hunder, Craig H Moskowitz, MD

Blood (2015) 126 (23): 3172.

https://doi.org/10.1182/blood.V126.23.3172.3172

Published: 2015

Journal Articles

Oprozomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Initial Results from the Dose Escalation Portion of a Phase 1b/2, Multicenter, Open-Label Study

Parameswaran N. Hari, MD, Kenneth H. Shain, MD PhD, Peter M. Voorhees, MD, Nashat Gabrail, MD, Muneer H. Abidi, MD, Jeffrey Zonder, MD, Ralph V. Boccia, MD, Paul G. Richardson, Linda L. Neuman, MD MBA, Sandra J. Dixon, MS, Claudia Paba Prada, MD

Blood (2014) 124 (21): 3453.

https://doi.org/10.1182/blood.V124.21.3453.3453

Published: 2014

Journal Articles

Outcomes of Second Autologous Peripheral Blood Stem Cell Transplant in Multiple Myeloma Patients with Renal Dysfunction

Lakshminarayanan Nandagopal, MD, J. Christine Ye, MD MSc, Richard Manasa, BS, Muneer H. Abidi, MD, Lois Ayash, MD, Lawrence G Lum, MD DSc, Joseph P. Uberti, MD PhD, Voravit Ratanatharathorn, MD, Jeffrey Zonder, MD, Divaya Bhutani, MD, Abhinav Deol, MD

Blood (2014) 124 (21): 5894.

https://doi.org/10.1182/blood.V124.21.5894.5894

Published: 2014

Journal Articles

Influence of Race on Outcomes in Multiple Myeloma Patients with Renal Dysfunction Undergoing High Dose Therapy Followed By Autologous Stem Cell Transplant

Lakshminarayanan Nandagopal, MD, J. Christine Ye, MD MSc, Marie Ventimiglia, Muneer H. Abidi, MD, Lois Ayash, MD, Jeffrey Zonder, MD, Lawrence G Lum, MD DSc, Joseph P. Uberti, MD PhD, Voravit Ratanatharathorn, MD, Divaya Bhutani, MD, Abhinav Deol, MD

Blood (2014) 124 (21): 5904.

https://doi.org/10.1182/blood.V124.21.5904.5904

Published: 2014

Journal Articles

Outcomes in Patients on Hemodialysis Who Undergo High Dose Therapy Followed By Autologous Peripheral Blood Stem Cell Transplant for Multiple Myeloma in the Era of Novel Agents

J. Christine Ye, MD MSc, Lakshminarayanan Nandagopal, MD, Marie Ventimiglia, Muneer H. Abidi, MD, Lois Ayash, MD, Lawrence G Lum, MD DSc, Joseph P. Uberti, MD PhD, Voravit Ratanatharathorn, MD, Jeffrey Zonder, MD, Divaya Bhutani, MD, Abhinav Deol, MD

Blood (2014) 124 (21): 2518.

https://doi.org/10.1182/blood.V124.21.2518.2518

Published: 2014

Journal Articles

The Aethera Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma

Craig H. Moskowitz, MD, Auayporn Nadamanee, MD, Tamas Masszi, MD PhD, Edward Agura, MD, Jerzy Holowiecki, MD PhD, Muneer H. Abidi, MD, Andy I Chen, MDPhD, Patrick J. Stiff, MD, Alessandro M. Gianni, MD, Angelo M. Carella, MD, Dzhelil Osmanov, MD, Veronika Bachanova, MD, John Sweetenham, MD, Anna Sureda, Dirk Huebner, MD, Emily K. Larsen, MS, Naomi N.H. Hunder, MD, Jan Walewski

Blood (2014) 124 (21): 673.

https://doi.org/10.1182/blood.V124.21.673.673

Published: 2014

Journal Articles

Patient-Reported Quality of Life Is an Independent Predictor of Survival after Allogeneic Hematopoietic Cell Transplantation: A Secondary Analysis from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902

William A. Wood, MD MPH, Jennifer Le-Rademacher, PhD, Mingwei Fei, MS, Brent R. Logan, PhD, Karen L Syrjala, PhD, Navneet S. Majhail, MD MS, John R. Wingard, MD, Muneer H. Abidi, MD, Nancy L. Geller, PhD, Juan Wu, MS, J. Douglas Rizzo, MD, Edward A Faber, DO, MS, Heather Jim, PhD, Paul Jacobsen, PhD, Mary M. Horowitz, MD MS, Stephanie J. Lee, MD MPH

Blood (2014) 124 (21): 206.

https://doi.org/10.1182/blood.V124.21.206.206

Published: 2014

Journal Articles

Incidence, Risk Factors and Outcome Of Cytomegalovirus (CMV) Viremia and CMV Gastroenteritis In Patients With Gastrointestinal Graft Versus Host Disease (GI GVHD)

Divaya Bhutani, MD, Gregory Dyson, MS, Richard Manasa, BS, Voravit Ratanatharathorn, MD, Abhinav Deol, MD, Muneer H. Abidi, MD, Zaid Al-Kadhimi, MD, Lois Ayash, MD, Lawrence G Lum, MD, DSc, Joseph P. Uberti, MD, PhD

Blood (2013) 122 (21): 2039.

https://doi.org/10.1182/blood.V122.21.2039.2039

Published: 2013

Journal Articles

Antithymocyte Globulin (Rabbit) Enhanced The Efficacy Of Tacrolimus and Mycophenolate For Graft-Versus-Host Disease Prophylaxis In Recipients Of Unrelated Stem Cell Transplant Resulting In Improvement Of Survival

Voravit Ratanatharathorn, MD, Abhinav Deol, MD, Lois Ayash, MD, Divaya Bhutani, MD, Lawrence G Lum, MD, DSc, Zaid Al-Kadhimi, MD, Muneer H. Abidi, MD, Marie Ventimiglia, Kendra Mellert, Joseph P. Uberti, MD, PhD

Blood (2013) 122 (21): 3300.

https://doi.org/10.1182/blood.V122.21.3300.3300

Published: 2013

Journal Articles

Low Incidence Of Severe Cgvhd and Late NRM In a Phase II Trial Of Thymoglobulin®, Tacrolimus and Sirolimus For Gvhd Prevention

Zaid Al-Kadhimi, MD, Alireza Eghtedar, MD, Zartash Gul, MD, Wei Chen, PhD, Daryn Smith, Abhinav Deol, MD, Muneer H. Abidi, MD, Lawrence G Lum, MD, DSc, Divaya Bhutani, MD, Lois Ayash, MD, Voravit Ratanatharathorn, MD, Joseph P. Uberti, MD, PhD

Blood (2013) 122 (21): 5471.

https://doi.org/10.1182/blood.V122.21.5471.5471

Published: 2013

Journal Articles

Exercise and Stress Management Training For Patients Undergoing Autologous Or Allogeneic Hematopoietic Cell Transplantation. Results From Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902

Stephanie J. Lee, MD, MPH, Jennifer Le Rademacher, PhD, Heather Jim, PhD, Karen L Syrjala, PhD, John R. Wingard, MD, PhD, Brent R. Logan, PhD, Juan Wu, MS, Navneet S. Majhail, MD, MS, William A. Wood, MD, MPH, J. Douglas Rizzo, MD, Nancy L. Geller, PhD, Carrie L. Kitko, MD, Edward A. Faber, Jr., DO, MS, Muneer H. Abidi, MD, Susan E. Slater, FNP, Mary M. Horowitz, MD, MS, Paul Jacobsen, Ph.D.

Blood (2013) 122 (21): 699.

https://doi.org/10.1182/blood.V122.21.699.699

Published: 2013

Journal Articles

Induction Of Anti-Myeloma Cellular and Humoral Immunity By Pre-Targeting Clonogenic Myeloma Cells Prior To Stem Cell Transplant With T Cells Armed With Anti-CD3 x Anti-CD20 Bispecific Antibody Leads To Transfer Of Cellular and Humoral Anti-Myeloma Immunity

Lawrence G Lum, MD, DSc, Archana Thakur, PhD, Zaid Al-Kadhimi, MD, Abhinav Deol, MBBS, MD, Lois Ayash, MD, Elyse N. Tomaszewski, BA, Hiroshi Yano, BS, Dana L Schalk, BS, MBA, Sri Vidya Kondadasula, MS, Patricia A. Steele, RN, BSN, Jeffrey A. Zonder, MD, Joseph P. Uberti, MD, PhD, Voravit Ratanatharathorn, MD, Muneer H. Abidi, MD

Blood (2013) 122 (21): 139.

https://doi.org/10.1182/blood.V122.21.139.139

Published: 2013

NARROW

Standard Risk Assessment Tools Fall Short to Assess Risk in Transplant Patients

Renal Toxicity with Carfilzomib in Multiple Myeloma: Secondary Analysis of SWOG S1304 Comparing Low-Dose Versus High-Dose Carfilzomib

Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse

Longer Term Follow up of the Â Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT)

Post-Transplant Cyclophosphamide Overcomes Graft-Versus-Host Disease Aggravation Induced By Extended Administration of Proteasome Inhibitors

Bendamustine, Carfilzomib, and Melphalan (BCM) Conditioning Prior to Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: A Feasibility Study

A Pilot Study of Peripheral Blood Hematopoietic Stem Cells Mobilization with the Combination of Bortezomib and G-CSF in Multiple Myeloma and Non-Hodgkin's Lymphoma Patients.

Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT): Results of the Randomized Phase III Trial SWOG S0777

Updated Efficacy and Safety Data from the AETHERA Trial of Consolidation with Brentuximab Vedotin after Autologous Stem Cell Transplant (ASCT) in Hodgkin Lymphoma Patients at High Risk of Relapse

Oprozomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Initial Results from the Dose Escalation Portion of a Phase 1b/2, Multicenter, Open-Label Study

Outcomes of Second Autologous Peripheral Blood Stem Cell Transplant in Multiple Myeloma Patients with Renal Dysfunction

Influence of Race on Outcomes in Multiple Myeloma Patients with Renal Dysfunction Undergoing High Dose Therapy Followed By Autologous Stem Cell Transplant

Outcomes in Patients on Hemodialysis Who Undergo High Dose Therapy Followed By Autologous Peripheral Blood Stem Cell Transplant for Multiple Myeloma in the Era of Novel Agents

The Aethera Trial: Results of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Brentuximab Vedotin in the Treatment of Patients at Risk of Progression Following Autologous Stem Cell Transplant for Hodgkin Lymphoma

Patient-Reported Quality of Life Is an Independent Predictor of Survival after Allogeneic Hematopoietic Cell Transplantation: A Secondary Analysis from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902

Incidence, Risk Factors and Outcome Of Cytomegalovirus (CMV) Viremia and CMV Gastroenteritis In Patients With Gastrointestinal Graft Versus Host Disease (GI GVHD)

Antithymocyte Globulin (Rabbit) Enhanced The Efficacy Of Tacrolimus and Mycophenolate For Graft-Versus-Host Disease Prophylaxis In Recipients Of Unrelated Stem Cell Transplant Resulting In Improvement Of Survival

Low Incidence Of Severe Cgvhd and Late NRM In a Phase II Trial Of Thymoglobulin®, Tacrolimus and Sirolimus For Gvhd Prevention

Exercise and Stress Management Training For Patients Undergoing Autologous Or Allogeneic Hematopoietic Cell Transplantation. Results From Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902

Induction Of Anti-Myeloma Cellular and Humoral Immunity By Pre-Targeting Clonogenic Myeloma Cells Prior To Stem Cell Transplant With T Cells Armed With Anti-CD3 x Anti-CD20 Bispecific Antibody Leads To Transfer Of Cellular and Humoral Anti-Myeloma Immunity

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only